Sodium-glucose cotransporter 2 inhibitors : A comprehensive review from cells to bedside
© 2022 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd..
Sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2is) are oral medications approved for type 2 diabetes mellitus. Interestingly, during recent years, they have been promisingly considered as new medications for cardiovascular and kidney diseases. However, the mechanisms underlying these new benefits are not fully understood. Thanks to the discovery of multiple modes of action, the simple picture about mechanisms of action of SGLT2is has become more and more complex. Besides their effects in diabetes, there is increasing evidence for their beneficial effects in heart failure and chronic kidney diseases. In addition, many studies have provided evidence for the fruitful effects of SGLT2is in atherosclerotic cardiovascular disease. In this study, we present mounting evidence for the complex action modes of SGLT2is and their current applications in clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Fundamental & clinical pharmacology - 37(2023), 3 vom: 08. Juni, Seite 481-492 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bagheri, Bahador [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.05.2023 Date Revised 12.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/fcp.12852 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349123128 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349123128 | ||
| 003 | DE-627 | ||
| 005 | 20231226041853.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/fcp.12852 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1163.xml |
| 035 | |a (DE-627)NLM349123128 | ||
| 035 | |a (NLM)36399066 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bagheri, Bahador |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sodium-glucose cotransporter 2 inhibitors |b A comprehensive review from cells to bedside |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.05.2023 | ||
| 500 | |a Date Revised 12.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd. | ||
| 520 | |a Sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2is) are oral medications approved for type 2 diabetes mellitus. Interestingly, during recent years, they have been promisingly considered as new medications for cardiovascular and kidney diseases. However, the mechanisms underlying these new benefits are not fully understood. Thanks to the discovery of multiple modes of action, the simple picture about mechanisms of action of SGLT2is has become more and more complex. Besides their effects in diabetes, there is increasing evidence for their beneficial effects in heart failure and chronic kidney diseases. In addition, many studies have provided evidence for the fruitful effects of SGLT2is in atherosclerotic cardiovascular disease. In this study, we present mounting evidence for the complex action modes of SGLT2is and their current applications in clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Sodium-glucose cotransporter 2 inhibitors | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a heart failure | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 650 | 7 | |a Sodium |2 NLM | |
| 650 | 7 | |a 9NEZ333N27 |2 NLM | |
| 700 | 1 | |a Yaribeygi, Habib |e verfasserin |4 aut | |
| 700 | 1 | |a Taherifard, Erfan |e verfasserin |4 aut | |
| 700 | 1 | |a Talasaz, Azita Hajhossein |e verfasserin |4 aut | |
| 700 | 1 | |a Bagheri, Haleh |e verfasserin |4 aut | |
| 700 | 1 | |a Darban, Mahboubeh |e verfasserin |4 aut | |
| 700 | 1 | |a Tabrizi, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Najafi, Siamak |e verfasserin |4 aut | |
| 700 | 1 | |a Khodadost, Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Akbari, Maryam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Fundamental & clinical pharmacology |d 1990 |g 37(2023), 3 vom: 08. Juni, Seite 481-492 |w (DE-627)NLM012737992 |x 1472-8206 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:3 |g day:08 |g month:06 |g pages:481-492 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/fcp.12852 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 3 |b 08 |c 06 |h 481-492 | ||